TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02037984

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 1x:1x:1x
Description: V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 1x:1x:1x
Description: V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 2x:2x:2x
Description: V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 2x:2x:2x
Description: V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 2x:1x:2x
Description: V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study: NCT02027337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinylestradiol /3 mg drospirenone
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/3 mg drospirenone
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mcg ethinylestradiol/2 mg cyproterone
Description: 1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study: NCT02573779

Intervention type: OTHER
Intervention: Observational - no intervention
Description: This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.

Intervention type: OTHER
Intervention: Observational - no intervention
Description: This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
Study: NCT01945580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolapse Repair
Description: Transvaginal anterior/apical pelvic organ prolapse repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolapse Repair
Description: Transvaginal anterior/apical pelvic organ prolapse repair
Study: NCT00958724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study: NCT03291171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0
Description: MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
Study: NCT02717377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Study: NCT01768247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG (human chorionic gonadotropin)
Description: 150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
Study: NCT01141777

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina platensis
Description: Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya bean
Description: Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
Study: NCT00833079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% manufactured by Taro
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study: NCT02037984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 1x:1x:2x
Description: V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 0.5x:0.5x:2x
Description: V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
Study: NCT00833079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic - Tacrolimus 0.1%
Description: Treatment applied as a thin layer to target area twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus Vehicle manufactured by Taro
Description: Treatment applied as a thin layer to target area twice daily for 14 days
Study: NCT02255578

Intervention type: DEVICE
Group type: OTHER
Intervention: Endobarrier treatment in PCOS
Description: the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women

Intervention type: DEVICE
Group type: OTHER
Intervention: Endobarrier treatment in PCOS
Description: the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women

Intervention type: DRUG
Group type: OTHER
Intervention: clomiphene citrate treatment
Study: NCT03654430

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography
Description: Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
Study: NCT00476801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: German manufactured UVA1 light emitting device
Description: The UVA1 dose will be up to 130 J/cm2.
Study: NCT03838328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
Study: NCT03373474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local-distal points association
Description: Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9.
Study: NCT03056547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced dyspnea
Description: Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger).
Study: NCT03229057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCP + Metformin
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCP + Placebo
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + Placebo
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study: NCT03185208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: See lithium carbonate arm
Study: NCT03838328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
Study: NCT04668989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A - (Test lens)
Description: Subjects will be randomized to wear test lenses for one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A - (Test lens)
Description: Subjects will be randomized to wear test lenses for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: kalifilcon A - (Control Lens)
Description: Subjects will be randomized to wear control lenses for one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A - (Control Lens)
Description: Subjects will be randomized to wear control lenses for one week.
Study: NCT00999401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and seliciclib
Description: sequential or concomitant administration of sapacitabine and seliciclib
Study: NCT04882020

Intervention type: DIAGNOSTIC_TEST
Intervention: cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
Description: compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.

Intervention type: DIAGNOSTIC_TEST
Intervention: cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
Description: compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
Study: NCT01080196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RENEW
Description: RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE.
Study: NCT02438462

Intervention type: OTHER
Intervention: Soluble Fibrin
Description: Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.

Intervention type: OTHER
Intervention: Soluble Fibrin
Description: Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
Study: NCT03908281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted Exercise
Description: Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postprandial Exercise
Description: Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
Study: NCT00189176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Study: NCT01914367

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cervarix
Description: 3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: 3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
Study: NCT03185208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: See placebo arm
Study: NCT03908736

Intervention type: DRUG
Group type: OTHER
Intervention: Zinc Picolinate 15 Mg
Description: zinc picolinate, 15 mg/day for 6 months
Study: NCT02379624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pectin
Description: Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
Study: NCT01649921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-gamma, Recombinant
Description: Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
Study: NCT00614861

Intervention type: OTHER
Intervention: Non-cancer pain management survey
Description: Non-cancer pain management survey
Study: NCT02795572

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU oral once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 100 mg oral once daily
Study: NCT03091777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-229
Description: GDC-229 is a vaginal gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Vaginal Gel 0.75%
Description: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive arm of the study
Study: NCT02914821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated tax via 3 cent per ounce price increase
Description: For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated tax via 3 cent per ounce price increase
Description: For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated tax via 3 cent per ounce price increase
Description: For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
Study: NCT00401895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS created with 8 or 10 mm covered stent
Description: creation of a shunt between hepatic vein and portal vein with PTFE-covered stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS created with 8 or 10 mm covered stent
Description: creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
Study: NCT04025671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Spray Naloxone
Description: Nasal spray naloxone device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Naloxone
Description: A vial of simulated naloxone and syringe with attached needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Improvised Nasal Atomizer
Description: A naloxone bristoject dose and nasal atomizer device.
Study: NCT00236951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose injection USP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose injection USP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable erythropoietin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable erythropoietin therapy
Study: NCT04043780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decompression prototype splint for carpal tunnel syndrome
Description: This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard splint for carpal tunnel syndrome
Description: This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
Study: NCT00706069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine oral
Description: Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
Study: NCT03498664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap for mucosectomy
Description: endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard snare for polypectomy
Description: endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
Study: NCT04411862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidyl Choline
Description: 2.1 g Phosphatidylcholine daily in addition to lifestyle modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification and health education by Clinical Pharmacist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Lifestyle modification and health education by Clinical Pharmacist
Study: NCT01631955

Intervention type: DRUG
Intervention: Ciprobay
Description: Ciprobay (250mg, bid, oral)
Study: NCT02267642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: monoclonal antibody
Study: NCT04304157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
Study: NCT01662414

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 1 sachect (10 g) 2times/ day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy protein
Description: 1 sachect (10g) 2times/day